High calcium risk in patients with diffuse large B-cell lymphoma during the chemotherapy: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2019.11.005
- VernacularTitle: 弥漫大B细胞淋巴瘤患者化疗中出现高钙危象一例并文献复习
- Author:
Lingxiao LIU
1
;
Jiakui ZHANG
;
Simeng CHEN
;
Yuanyuan SHEN
;
Qianshan TAO
;
Zhimin ZHAI
Author Information
1. Department of Hematology, Bio-Medical Research Center, the Second Affiliated Hospital of Anhui Medical University, Hematologic Diseases Research Center of Anhui Medical University, Hefei 230601, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, large B-cell, diffuse;
Hypercalcemia;
Antineoplastic combined chemotherapy protocols
- From:
Journal of Leukemia & Lymphoma
2019;28(11):663-667
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To improve the understanding of high calcium risk in patients with diffuse large B-cell lymphoma (DLBCL) during the chemotherapy.
Methods:The diagnosis and treatment of high calcium risk in one patient with DLBCL during the chemotherapy in the Second Affiliated Hospital of Anhui Medical University was retrospectively analyzed, and the relevant literatures were reviewed.
Results:A 52-year-old man who was diagnosed with DLBCL (non-specific, non-germinal center source; stage Ⅳ group A; International prognosis index score 4 points, high-risk group) in June 2017. Two times R-CHOP chemotherapy was performed before diagnosis. This patient was admitted to the hospital for the third chemotherapy, and the disease assessment showed that the enlarged lymph nodes were not significantly smaller than before, and the tumor burden was still high. Therefore, the chemotherapy regimen was adjusted to R-GDP regimen. However, on the 8th day after the end of rituximab treatment, the patient had head pain, which might be related to the patient's poor sleep and primary invasion of the primary disease (blood calcium: 2.94 mmol/L). And then the ibuprofen and diuresis treatments were given, but the symptoms were still gradually worsening, and vomiting appeared on the 9th day, systemic fatigue with drowsiness and irritability appeared on the 12th day. Review blood calcium: 5.02 mmol/L. Adequate fluid hydration, diuretic, renal replacement treatments were given, and the level of blood calcium gradually returned to normal. Finally, the patient's symptoms were improved significantly, and he successfully completed R-GDP chemotherapy.
Conclusion:If a DLBCL patient has symptoms such as headache, lethargy, irritability or even coma during the chemotherapy, it is necessary to alert the possibility of hypercalcemia and to timely improve the relevant examination and make symptomatic treatment.
